Welcome to our dedicated page for Glaukos SEC filings (Ticker: GKOS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Glaukos Corporation filings document the regulatory record for an ophthalmic pharmaceutical and medical technology company with common stock listed on the New York Stock Exchange under GKOS. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary net sales information, supplemental business summaries, and Regulation FD investor presentations.
The company’s proxy materials provide governance and executive-compensation disclosures, including equity-award and pay-versus-performance information. These filings also identify Glaukos as a Delaware corporation and frame disclosure around its glaucoma, corneal-disorder, and retinal-disease therapies, commercial products, risk disclosures, and public-company reporting obligations.
Glaukos Corporation is sharing an investor presentation that outlines its growth strategy, diversified ophthalmic pipeline and recent financial performance. The company highlights 12 commercialized products and 13 disclosed pipeline programs across glaucoma, keratoconus, blepharitis, myopia and retinal disease.
Net sales grew from $283 million in 2022 to $507 million in 2025, supported by innovations such as iStent, iDose TR and keratoconus therapies Photrexa and Epioxa. The presentation cites 30% 2025 topline growth, a 20% 10‑year revenue CAGR and roughly $800 million invested in R&D since 2018.
For 1Q 2026, Glaukos reports an adjusted gross margin of 84% and cash and equivalents of $281 million with no debt as of March 31, 2026. Sales guidance for 2026 has a midpoint of $627.5 million, underscoring expectations for continued expansion supported by global infrastructure in 17 countries and more than 300 commercial personnel.
Fidelity Brokerage Services LLC submitted a Form 144 notifying an intent to sell 19,573 shares of Common Stock of GKOS as reported on 05/01/2026. The shares arise from multiple restricted stock vesting events dated 12/13/2024 through 04/01/2025, with individual vesting amounts listed in the filing.
Glaukos Corp. notice of proposed resale of 10,000 shares of Common Stock by Fidelity Brokerage Services LLC under Rule 144. The filing lists recent open‑market dispositions by Alex R. Thurman totaling 4,657 shares across March 17, 24 and 25, 2026, with cash proceeds reported for each trade.
Glaukos Corporation reported strong top-line growth but continued losses for the quarter ended March 31, 2026. Net sales rose to $150.6 million from $106.7 million a year earlier, driven mainly by higher U.S. glaucoma revenue from the iDose TR sustained-release implant and growth in international glaucoma procedures.
Corneal health revenue also increased as Photrexa and the early Epioxa launch contributed more U.S. sales. Gross margin was 78%, similar to last year, but higher selling, general and administrative expenses of $92.9 million and research and development spending of $44.1 million kept the company in the red, with a net loss of $19.8 million, or $0.34 per share.
Glaukos ended the quarter with $280.5 million in cash, cash equivalents, short-term investments and restricted cash. The company highlighted an option agreement for potential new drug technology and noted a permanent HCPCS J-code for Epioxa effective July 2026, which is expected to simplify U.S. reimbursement for its new keratoconus therapy.
Glaukos Corp reported that Vanguard Capital Management beneficially owns 2,947,047 shares of Common Stock, representing 5.07% of the class. The filing states Vanguard has sole dispositive power over 2,947,047 shares and sole voting power for 438,276 shares.
The Schedule 13G notes these holdings include securities held for Vanguard funds and managed accounts; the filing is signed by Vanguard's Head of Global Fund Administration.
Glaukos Corporation reported strong first quarter 2026 growth but remains unprofitable. Net sales reached $150.6 million, up 41% year-over-year, driven mainly by glaucoma products, including U.S. Glaucoma revenue of $93.5 million and growing adoption of the iDose TR therapy.
GAAP gross margin was about 78%, with non-GAAP gross margin near 84%. The company posted a GAAP net loss of $19.8 million, or ($0.34) per share, and a non-GAAP net loss of $10.4 million, or ($0.18) per share. Glaukos ended the quarter with $280.5 million in cash, equivalents, short-term investments and restricted cash and no debt, and raised its 2026 net sales guidance to $620–$635 million.
Vanguard Portfolio Management reports beneficial ownership of 3,256,962 shares of Glaukos Corp common stock, representing 5.6% of the class as of 03/31/2026. The filer discloses sole dispositive power over 3,256,962 shares and sole voting power for 48,599 shares. The statement was filed as a Schedule 13G and signed on 04/29/2026.
Glaukos Corporation has issued its 2026 proxy statement for the May 28, 2026 virtual annual meeting, asking stockholders to elect two Class II directors, approve executive pay on an advisory basis, and ratify Ernst & Young LLP as auditor.
For 2025, Glaukos reports net sales of $507 million and cash, equivalents, restricted cash and short-term investments of $283 million as of December 31, 2025. The eight‑member board is 88% independent, 38% women, and 25% from underrepresented communities, with an average age of 60.6 years and average tenure of 12.6 years.
The proxy highlights say‑on‑pay support of 97.7% at the 2025 meeting, a pay program emphasizing variable, performance‑linked compensation, stock ownership and clawback policies, and strong governance practices including overboarding limits, an updated code of conduct, active cybersecurity oversight, and expanding sustainability and climate initiatives.